The standard of care in RA is treat-to-target of remission or low disease activity state (LDAS). Integral to this is the regular assessment of disease activity. Patient-derived Disease Activity Score 2 (PDAS2) was developed to allow RA patients to self-assess. Validation, corresponding disease activity statuses cut-points and response criteria had been published. PDAS2 scores <3.8,.0, >5.0 correspond to remission, LDAS, moderate and high disease activities respectively. PDAS2 can be recorded by patients in-between clinic visits. Objectives: To explore the clinical utility of PDAS2 on remission, flare and need of drug adjustment Methods: A cohort of 100 consecutive RA patients was recruited to complete PDAS2 score at home fortnightly in between two consecutive rheumatology clinics. Patients would return the forms when they attended the second clinic. Rheumatologists adjusted treatment according to disease activity while blinded to the scores of PDAS2 recorded at home. AUC of PDAS2 was calculated from the mean of (PDAS2 score multiplied by the time interval between scores). They were compared with disease activity at the first and second visits. The change of PDAS2 score for those patients having SDAI flare-up (from remission/LDAS to moderate/high disease activity) was compared to those didn't flare-up using unpaired T-test. Receiver Operator Characteristic curve was used to determine the cut-point for AUC-PDAS2 increment to predict flare-up and the cut-point of PDAS2 score for rheumatologists to escalate anti-rheumatic drugs. Results: Mean age of the cohort was 60 years, mean RA duration 14 years, 90% female, 71% sero-positive and 48% in remission/low disease activity. 89 patients (89%) returned written questionnaires which were done 7.8±3.5 times (mean±standard deviation) (range 1-16) for a follow-up interval of 17.5±9.4 weeks (range 3.9-60.3). Disease activities in first and second visits are shown in Table. Remission: For the 14 patients in SDAI remission in both visits, 13/14 were in AUC-PDAS2 remission, and 1/14 in LDAS. There were 47, 45 and 37 out of 89 patients in SDAI, CDAI and DAS28 remission/LDAS respectively -they were all in AUC-PDAS2 remission/LDAS. Flare-up: There were 10/89 patients in SDAI remission/LDAS in first visit and moderate/high activity in second visit. Their AUC-PDAS2 score rose by 0.33±0.35 points compared to 0.01±0.32 who had no flare-up (p=0.002). ROC curve AUC was 0.80 (95% CI: 0.64, 0.95) (p=0.002), with optimal cut-point at increment of AUC-PDAS2 score by 0.11 to predict flare, sensitivity and specificity both being 80%. Moreover, rheumatologists decided to escalate anti-rheumatic drugs in 15/89 patients. ROC curve AUC was 0.71 (95% CI: 0.56, 0.86) (p=0.01), with optimal cut-point at PDAS2 score 4.33 to predict the need of escalating anti-rheumatic drugs, sensitivity being 60% and specificity 77%.
Background:
The standard of care in RA is treat-to-target of remission or low disease activity state (LDAS). Integral to this is the regular assessment of disease activity. Patient-derived Disease Activity Score 2 (PDAS2) was developed to allow RA patients to self-assess. Validation, corresponding disease activity statuses cut-points and response criteria had been published. PDAS2 scores <3.8, .0, >5.0 correspond to remission, LDAS, moderate and high disease activities respectively. PDAS2 can be recorded by patients in-between clinic visits. Objectives: To explore the clinical utility of PDAS2 on remission, flare and need of drug adjustment Methods: A cohort of 100 consecutive RA patients was recruited to complete PDAS2 score at home fortnightly in between two consecutive rheumatology clinics. Patients would return the forms when they attended the second clinic. Rheumatologists adjusted treatment according to disease activity while blinded to the scores of PDAS2 recorded at home. AUC of PDAS2 was calculated from the mean of (PDAS2 score multiplied by the time interval between scores). They were compared with disease activity at the first and second visits. The change of PDAS2 score for those patients having SDAI flare-up (from remission/LDAS to moderate/high disease activity) was compared to those didn't flare-up using unpaired T-test. Receiver Operator Characteristic curve was used to determine the cut-point for AUC-PDAS2 increment to predict flare-up and the cut-point of PDAS2 score for rheumatologists to escalate anti-rheumatic drugs. Results: Mean age of the cohort was 60 years, mean RA duration 14 years, 90% female, 71% sero-positive and 48% in remission/low disease activity. 89 patients (89%) returned written questionnaires which were done 7.8±3.5 times (mean±standard deviation) (range 1-16) for a follow-up interval of 17.5±9.4 weeks (range 3.9-60.3). Disease activities in first and second visits are shown in Table. Remission: For the 14 patients in SDAI remission in both visits, 13/14 were in AUC-PDAS2 remission, and 1/14 in LDAS. There were 47, 45 and 37 out of 89 patients in SDAI, CDAI and DAS28 remission/LDAS respectively -they were all in AUC-PDAS2 remission/LDAS. Flare-up: There were 10/89 patients in SDAI remission/LDAS in first visit and moderate/high activity in second visit. Their AUC-PDAS2 score rose by 0.33±0.35 points compared to 0.01±0.32 who had no flare-up (p=0.002). ROC curve AUC was 0.80 (95% CI: 0.64, 0.95) (p=0.002), with optimal cut-point at increment of AUC-PDAS2 score by 0.11 to predict flare, sensitivity and specificity both being 80%. Moreover, rheumatologists decided to escalate anti-rheumatic drugs in 15/89 patients. ROC curve AUC was 0.71 (95% CI: 0.56, 0.86) (p=0.01), with optimal cut-point at PDAS2 score 4.33 to predict the need of escalating anti-rheumatic drugs, sensitivity being 60% and specificity 77%.
Conclusions:
PDAS2 scoring by patients in-between follow-up is feasible and useful in reassuring RA patients kept in remission/LDAS, informing a potential flare from previous remission/LDAS state, and predicting rheumatologists' decision to escalate anti-rheumatic drugs. AUC-PDAS2 concept is useful in development of smartphone application for patient use. Methods: We analyzed 15,101 patients registered in the Japanese National Database (NinJa 2015). As the OMERACT group proposed, patients with tender joint count (TJC) of 0, swollen joint count (SJC) of 0, and erythrocyte sedimentation rate (ESR) ≤10 mm/hour or patients with five of the following seven criteria, namely, pain ≤2, SJC ≤1, TJC ≤1, HAQ ≤0.5, physician's global ≤1.5, patient's global ≤2, and ESR ≤20, were considered to be in MDA.
1 The ROC curve was used to obtain the best cut-off points for the SDAI, CDAI, and RAPID3-based definitions of MDA, which emerged as good predictors of MDA as defined by the core dataset. To compare the usefulness of the indices, the interclass correlation of MDA in DAS28, SDAI/CDAI, and RAPID3 was compared to that of low disease activity (LDA). Results: 57.6% of patients (5,629/9,767) were categorized as having MDA, and 29% of patients (4,003/13,781) were categorized as Boolean remissions. In the ROC analysis, the area under the curve for DAS28, SDAI, CDAI, and RAPID3 was 0.911, 0.955, 0.953, and 0.930, respectively. Based on the Youden index, SDAI ≤5.3, CDAI ≤4.8, and RAPID3 ≤5 were defined as SDAI, CDAI, and RAPID3-based MDA, respectively. The sensitivity and specificity of the DAS28, SDAI, CDAI, and RAPID3-based definitions were higher than those of the DAS28-based definition, with a sensitivity of 81.5%, 89.2%, 88.8%, and 90.0%, respectively, and a specificity of 83.5%, 89.4%, 89.9%, and 88.4%, respectively. Each index-based definition of MDA showed better interclass correlation than that of LDA; 
